COPD patient demographics
| Treatment group | |||
| Placebo# | 50 µg RV568# | 100 µg RV568# | |
| Age years | 66±5 | 62±5 | 60±5 |
| Sex | |||
| Male | 7 | 4 | 4 |
| Female | 4 | 6 | 6 |
| Race | |||
| White | 10 | 10 | 9 |
| Other | 0 | 0 | 1 |
| Weight kg | 78.9±13.6 | 70.9±14.0 | 70.6±13.1 |
| Height cm | 173±12 | 164±12 | 164±10 |
| BMI kg·m−2 | 26.3±2.8 | 26.7±5.5 | 26.4±4.3 |
| Post-bronchodilator FEV1 % predicted | 67±10 | 65±9 | 62±11 |
| Post-bronchodilator FEV1/FVC ratio % | 52.2±10.2 | 49.2±12.5 | 48.1±11.6 |
| Smoking status | |||
| Current | 5 | 5 | 4 |
| Former | 5 | 5 | 6 |
| COPD therapy | |||
| Single (SABA, LABA or LAMA) | 2 | 4 | 4 |
| Dual (ICS/LABA or LABA/LAMA) | 2 | 2 | 2 |
| Triple (ICS/LABA/LAMA) | 6 | 4 | 4 |
Data are presented as mean±sd or n. COPD: chronic obstructive pulmonary disease; BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SABA: short-acting beta agonists; LABA: long-acting beta agonists; LAMA: long-acting muscarinic antagonists; ICS: inhaled corticosteroids. #: n=10.